ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Harmony Biosciences Enrolls First Patient in Pitolisant Trial for Excessive Daytime Sleepiness
December 17, 2020Harmony Biosciences announced the first patient has been enrolled in a Phase 2 trial evaluating the safety and efficacy of pitolisant for the treatment of excessive daytime sleepiness (EDS) and other key symptoms in patients with Prader-Willi Syndrome. -
FDA Approves Wakix (pitolisant), a First-in-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy
August 16, 2019Harmony Biosciences, LLC (Harmony) announced today that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.
Pharma Sources Insight January 2025
